Symbols

AURA

Aura Biosciences·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Stock Price Surged Significantly

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AURA

Aura Biosciences, Inc.

A biotechnology company that develops novel targeted therapies for cancer

Industry

Biological Technology

Established Date

Listing Date

10/29/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

113

Fiscal Year Ends

12-31

Website

www.aurabiosciences.com

Security Type

Common stock

Office address

80 Guest Street Boston MA 02135

Business

Introduction

Aura Biosciences, Inc., was incorporated in January 2009 under the laws of the State of Delaware. The company is a clinical-stage biotechnology company that develops precision therapies for the treatment of solid tumors designed to protect organ function. The company's lead product candidate, bel-sar, is in late-stage clinical development for the treatment of patients with early-stage choroidal melanoma, and is also in clinical development for other ocular tumor indications and bladder cancer.

Company Financials

EPS

AURA has released its 2025 Q4 earnings. EPS was reported at -0.34, versus the expected -0.43, beating expectations. The chart below visualizes how AURA has performed over recent quarters, highlighting trends in earnings surprises.